BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18510642)

  • 1. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.
    Cattaneo D; Baldelli S; Perico N
    Am J Transplant; 2008 Jul; 8(7):1374-83. PubMed ID: 18510642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.
    Ng FL; Holt DW; MacPhee IA
    Expert Opin Pharmacother; 2007 Sep; 8(13):2045-58. PubMed ID: 17714059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?
    Burckart GJ; Liu XI
    Ther Drug Monit; 2006 Feb; 28(1):23-30. PubMed ID: 16418689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practicability of pharmacogenetics in transplantation medicine.
    van Gelder T; van Schaik RH; Hesselink DA
    Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
    Picard N; Bergan S; Marquet P; van Gelder T; Wallemacq P; Hesselink DA; Haufroid V
    Ther Drug Monit; 2016 Apr; 38 Suppl 1():S57-69. PubMed ID: 26469711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.
    Kurzawski M; Droździk M
    Pharmacogenomics; 2013 Jul; 14(9):1099-118. PubMed ID: 23837483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).
    Woillard JB; Chouchana L; Picard N; Loriot MA;
    Therapie; 2017 Apr; 72(2):285-299. PubMed ID: 28318610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
    Ekbal NJ; Holt DW; Macphee IA
    Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
    Zhao W; Fakhoury M; Jacqz-Aigrain E
    Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
    MacPhee IA; Fredericks S; Holt DW
    Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic factors for individual administration of immunosuppressants in organ transplantation.
    Yu SF; Wu LH; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetics of immunosuppressants].
    Cojutti PG; Baraldo M
    G Ital Nefrol; 2015; 32(2):. PubMed ID: 26005938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and immunosuppressive drugs.
    Hronová K; Šíma M; Světlík S; Matoušková O; Slanař O
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):821-35. PubMed ID: 25301406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.
    Fredericks S; Holt DW; MacPhee IA
    Am J Pharmacogenomics; 2003; 3(5):291-301. PubMed ID: 14575518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
    Anglicheau D; Legendre C; Beaune P; Thervet E
    Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
    Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
    World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.